Cyclacel Pharmaceuticals jumps on Janney initiation

|About: Cyclacel Pharmaceuticals, Inc. (CYCC)|By:, SA News Editor

Cyclacel Pharmaceuticals (CYCC) rises 5% premarket (on top of 10% in Monday's regular session) in what looks like a reaction to an initiation (Buy) at Janney Montgomery.

Price target is $10.

Bullish call is more than likely tied to the company's Phase 3 AML candidate sapacitabine.